Search results
Author(s):
Kerry Layne
,
Albert Ferro
Added:
3 years ago
Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation. Antiplatelet therapy has formed the backbone of ACS management for decades and the drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. The main risk…
View more
Novel Oral Antiplatelet Agents
Author(s):
Suzanne J Baron
,
Robert P Giugliano
Added:
3 years ago
Article
Author(s):
Diego Penela
,
Maríbel Diaz-Ricart
,
Magda Heras
Added:
3 years ago
The usual underlying mechanism of acute coronary syndromes (ACSs) is a thrombotic event caused by the rupture or erosion of an atherosclerotic plaque. In this scenario, platelets and thrombin are key players. Thus, understanding the physiopathology of platelet activation is of paramount importance in the treatment of acute coronary ischaemia. There is ample evidence showing that adequate…
View more
Author(s):
Jean-Philippe Collet
,
Jochem Wouter van Werkum
Added:
3 years ago
Antiplatelet therapy is the standard of care for patients with acute coronary syndromes (ACS) and/or patients undergoing percutaneous coronary intervention (PCI) with stenting.1–3 Plaque rupture and/or iatrogenic vascular damage during PCI would normally result in the development of intravascular thrombus. Findings across multiple investigations consistently demonstrate the effectiveness of dual…
View more
Author(s):
Tamara García Camarero
,
José M de la Torre Hernández
Added:
3 years ago
The use of dual antiplatelet therapy (DAPT) after stent implantation in a percutaneous coronary intervention (PCI) is the standard treatment. The first randomised controlled trial (RCT) to establish the superiority of DAPT versus oral anticoagulant treatment among patients undergoing PCI was the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial, published in 1996.1 Since then, more…
View more
Author(s):
Josep Gradolí
,
Verónica Vidal
,
Adrian JB Brady
,
et al
Added:
3 years ago
Atherosclerotic cardiovascular disease (CVD) comprises a large number of related pathologies, including ischaemic heart disease and peripheral arterial disease (PAD).1 This group of illnesses is the main cause of global morbidity and mortality and its prevalence increases remorselessly.2
Despite implementation of guideline-based therapy and optimal medical treatment, patients with established…
View more
Author(s):
Haider Aldiwani
,
Suzan Mahdai
,
Ghaith Alhatemi
,
et al
Added:
2 years ago
Stable Angina Medical Therapy
Author(s):
Talla A Rousan
,
Udho Thadani
Added:
3 years ago
Article
Author(s):
Raffaele De Caterina
,
Giulia Renda
Added:
3 years ago
Limitations of Coumarin Derivatives in Atrial Fibrillation and the Quest for New Drugs
Warfarin and similar coumarin derivatives (vitamin K antagonists [VKAs]) clearly have the greatest efficacy among the currently available treatments (mostly aspirin) in preventing stroke in atrial fibrillation (AF).1 However, they carry a substantial risk of major bleeding (approximately 1.2% per year) and…
View more
Author(s):
Jack Wei Chieh Tan
,
Derek P Chew
,
Muhamad Ali SK Abdul Kader
,
et al
Added:
3 years ago